Supplement

You have full text access to this OnlineOpen article

Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States†‡

  1. Xiaocheng Wu MD, MPH1,§,*,
  2. Genevieve Matanoski Dr PhD, MD2,3,
  3. Vivien W. Chen PhD1,
  4. Mona Saraiya MD, MPH4,
  5. Steven S. Coughlin PhD4,
  6. Jessica B. King MPH4,
  7. Xu-Guang Tao MD, PhD5

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23757

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2873–2882, 15 November 2008

Additional Information

How to Cite

Wu, X., Matanoski, G., Chen, V. W., Saraiya, M., Coughlin, S. S., King, J. B. and Tao, X.-G. (2008), Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer, 113: 2873–2882. doi: 10.1002/cncr.23757

Author Information

  1. 1

    Louisiana Tumor Registry, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana

  2. 2

    Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

  3. 3

    Washington DC Cancer Registry, Washington, District of Columbia

  4. 4

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  5. 5

    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

  1. §

    Fax: (504) 568-5800.

*Louisiana Tumor Registry, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, 1615 Poydras Street, Suite 1400, New Orleans, LA 70112

  1. †

    The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. ‡

    This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 15 MAY 2008
  4. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (144K)

REFERENCES

  • 1
    Jemal A,Murray T,Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10–30.
    Direct Link:
  • 2
    Hellman K,Silfversward C,Nilsson B,Hellstrom AC,Frankendal B,Pettersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. Int J Gynecol Cancer. 2004; 14: 491–501.
    Direct Link:
  • 3
    Carter JJ,Madeleine MM,Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001; 61: 1934–1940.
  • 4
    Daling J,Madeleine M,Schwartz S, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263–270.
  • 5
    Daling JR,Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. In: MunozN,BoschFX,ShahKV,MeheusA, eds. The Epidemiology of Human Papillomavirus and Cervical Cancer (IARC Scientific Publication No. 119). Lyon, France: IARC; 1992: 223–241.
  • 6
    Brinton LA,Nasca PC,Mallin K, et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol. 1990; 38: 49–54.
  • 7
    McFarlane MJ,Feinstein AR,Horwitz RI. Diethylstilbestrol and clear cell vaginal carcinoma. Reappraisal of the epidemiologic evidence. Am J Med. 1986; 81: 855–863.
  • 8
    Franco EL. Epidemiology of anogenital warts and cancer. Obstet Gynecol Clin North Am. 1996; 23: 597–623.
  • 9
    Merino MJ. Vaginal cancer: the role of infectious and environmental factors. Am J Obstet Gynecol. 1991; 165(4 pt 2): 1255–1262.
  • 10
    Srodon M,Stoler MH,Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30: 1513–1518.
  • 11
    Hampl M,Sarajuuri H,Wentzensen N,Bender H,Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 1361–1368.
  • 12
    Parkin D,Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S11–S25.
  • 13
    Castle PE,Schiffman M,Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis. 2004; 190: 458–467.
  • 14
    Schiffman M,Castle PE,Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890–907.
  • 15
    Dodge JA,Eltabbakh GH,Mount SL, et al. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001; 83: 363–369.
  • 16
    Aho M,Vesterinen E,Meyer B, et al. Natural history of vaginal intraepithelial neoplasia. Cancer. 1991; 68: 195–197.
    Direct Link:
  • 17
    Indermaur MD,Martino MA,Fiorica JV, et al. Upper vaginectomy for the treatment of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2005; 193: 577–580; discussion 580–581.
  • 18
    Moscicki AB,Hills N,Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001; 285: 2995–3002.
  • 19
    Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369: 1693–1702.
  • 20
    Watson M,Saraiya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2841–2854.
    Direct Link:
  • 21
    Harwell TS,Miller SH,Lemons DL, et al. Cancer incidence in Montana: rates for American Indians exceed those for whites. Am J Prev Med. 2006; 30: 493–497.
  • 22
    YoungJJ,RoffersS,RiesL,FritzA,HurlbutA, eds. SEER Summary Staging Manual—2000: Codes and Coding Instructions. National Cancer Institute. NIH Publication No. 01-4969, Bethesda, Md: National Cancer Institute; 2001.
  • 23
    Surveillance, Epidemiology, and End Results Program. Extent of Disease: Code and Coding Instructions. Bethesda, Md: National Institutes of Health, National Cancer Institute; 1977.
  • 24
    Howe H,Jamison P,Havener L,Chen V,Ries L. Site-specific comparison of summary stage 1977 and summary stage 2000 coding. Available at: http//www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=397. Accessed on July 23, 2008.
  • 25
    Tiwari RC,Clegg LX,Zou Z,Tiwari RC,Clegg LX,Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547–569.
  • 26
    Parkin DM,Whelan SL,Ferlay J,Teppo L,Thomas D,Thomas DB.Cancer Incidence in Five Continents. Vol VIII. Lyon, France: International Agency for Research on Cancer; 2002.
  • 27
    Shambaugh E,Young JJr,Zippin C,Lum D,Akers C,Weiss M. SEER Program Self-Instructional Manual for Cancer Registrars. Book 7: Statistics and Epidemiology for Cancer Registrars. National Cancer Institute. NIH Publication No.94-3766. Bethesda, Md: National Institutes of Health; 1994.
  • 28
    Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050, US Bureau of the Census, Current Population Reports, P25-1130. Washington, DC: US Government Printing Office; 1996.
  • 29
    Revzina NV,Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005; 16: 528–537.
  • 30
    Kahn JA,Lan D,Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007; 110: 87–95.
  • 31
    Magnusson P,Sparen P,Gyllensten U. Genetic link to cervical tumours. Nature. 1999; 400: 29–30.
  • 32
    Levi F,Randimbison L,La Vecchia C. Descriptive epidemiology of vulvar and vaginal cancers in Vaud, Switzerland, 1974-1994. Ann Oncol. 1998; 9: 1229–1232.
  • 33
    Heusch WL,Maneckjee R,Heusch WL,Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis. 1998; 19: 551–556.
  • 34
    Wright SC,Zhong J,Zheng H, et al. Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J. 1993; 7: 1045–1051.
  • 35
    Poppe WA,Peeters R,Daenens P, et al. Tobacco smoking and the uterine cervix: cotinine in blood, urine and cervical fluid. Gynecol Obstet Invest. 1995; 39: 110–114.
  • 36
    Gunnell AS,Tran TN,Torrang A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2141–2147.
  • 37
    Hildesheim A,Han C,Brinton L, et al. Sexually transmitted agents and risk of carcinoma of the vagina. Int J Gynecol Cancer. 1997; 7: 251–255.
    Direct Link:
  • 38
    Kleinerman R,Kosary C,Hildesheim A. Chapter 8: new malignancies following cancer of the cervix uteri, vagina, and vulva. In: CurtisRE,FreedmanDM,RonE, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publication No. 05-5302. Bethesda, Md: National Cancer Institute; 2006.
  • 39
    Pride GL,Buchler DA. Carcinoma of vagina 10 or more years following pelvic irradiation therapy. Am J Obstet Gynecol. 1977; 127: 513–517.
  • 40
    Ryberg M,Lundell M,Nilsson B,Pettersson F. Malignant disease after radiation treatment of benign gynaecological disorders. A study of a cohort of metropathia patients. Acta Oncol. 1990; 29: 563–567.
  • 41
    Chyle V,Zagars GK,Wheeler JA,Wharton JT,Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1996; 35: 891–905.
  • 42
    Freeman G,Lethbridge-Cejku M. Access to health care among Hispanic or Latino women: United States, 2000-2002. Adv Data. 2006;( 368): 1–25.
  • 43
    Howe H,Wu X,Edwards B, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006; 107: 1711–1742.
    Direct Link:
  • 44
    Kagawa-Singer M,Pourat N. Asian American and Pacific Islander breast and cervical carcinoma screening rates and Healthy People 2000 objectives. Cancer. 2000; 89: 696–705.
    Direct Link:
  • 45
    Chen MJ. Cancer health disparities among Asian Americans: what we do and what we need to do. Cancer. 2005; 104( 12 suppl): 2895–2902.
    Direct Link:
  • 46
    U.S. Department of Health and Human Services. 2004 National Healthcare Disparities Report. Rockville, Md: Agency for Healthcare Research and Quality; 2004.
  • 47
    Swan J,Breen N,Coates R,Rimer B. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 1528–1540.
    Direct Link:
  • 48
    Hewitt M,Devesa S,Breen N. Cervical cancer screening among US women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270–278.
  • 49
    Saslow D,Runowicz C,Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342–362.
    Direct Link:
  • 50
    US Preventive Services Task Force. Cervical Cancer—Screening. Release date, January 2003. Available at: http//www.ahrq.gov/clinic/uspstf/uspscerv.htm. Accessed July 30, 2007.
  • 51
    Kolb B,Wallace AM,Hill D,Royce M. Disparities in cancer care among racial and ethnic minorities. Oncology (Williston Park). 2006; 20: 1256–1261; discussion 1261, 1265, 1268–1270.
  • 52
    Hamel MB,Teno JM,Goldman L, et al. Patient age and decisions to withhold life-sustaining treatments from seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med. 1999; 130: 116–125.
  • 53
    SEER. The SEER Program Code Manual, 3rd ed, revision 1 (updated January 2003). NIH Publication No. 98-1999. Bethesda, Md: National Institutes of Health, National Cancer Institute; 1998.
  • 54
    HavenerL,HultstromD, eds.Standard for Cancer Registries Volume II: Data Standard and Data Dictionary, 11th ed, version 11.1. Springfield, Ill: North American Association of Central Cancer Registries; 2006.
View Full Article (HTML) Get PDF (144K)